- Home
- ADIL vs EVOK Comparison
ADIL vs EVOK Comparison
Compare ADIL & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- EVOK
- Stock Information
- Founded
- ADIL 2010
- EVOK 2007
- Country
- ADIL United States
- EVOK United States
- Employees
- ADIL N/A
- EVOK N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- EVOK Health Care
- Exchange
- ADIL Nasdaq
- EVOK Nasdaq
- Market Cap
- ADIL 4.8M
- EVOK 4.2M
- IPO Year
- ADIL 2018
- EVOK 2013
- Fundamental
- Price
- ADIL $0.37
- EVOK $5.50
- Analyst Decision
- ADIL Strong Buy
- EVOK
- Analyst Count
- ADIL 1
- EVOK 0
- Target Price
- ADIL $8.00
- EVOK N/A
- AVG Volume (30 Days)
- ADIL 23.1M
- EVOK 7.2M
- Earning Date
- ADIL 08-12-2025
- EVOK 08-12-2025
- Dividend Yield
- ADIL N/A
- EVOK N/A
- EPS Growth
- ADIL N/A
- EVOK N/A
- EPS
- ADIL N/A
- EVOK N/A
- Revenue
- ADIL N/A
- EVOK $11,594,083.00
- Revenue This Year
- ADIL N/A
- EVOK $57.82
- Revenue Next Year
- ADIL N/A
- EVOK $59.12
- P/E Ratio
- ADIL N/A
- EVOK N/A
- Revenue Growth
- ADIL N/A
- EVOK 89.89
- 52 Week Low
- ADIL $0.22
- EVOK $1.94
- 52 Week High
- ADIL $3.00
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- ADIL 46.63
- EVOK 74.84
- Support Level
- ADIL $0.30
- EVOK $2.52
- Resistance Level
- ADIL $0.41
- EVOK $9.88
- Average True Range (ATR)
- ADIL 0.06
- EVOK 0.49
- MACD
- ADIL 0.02
- EVOK 0.39
- Stochastic Oscillator
- ADIL 48.13
- EVOK 49.19
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.